About Event

The 5th Annual Gene Therapy Immunogenicity Summit– What’s it About?

The industry-leading forum focussed on ways to predict, monitor, and mitigate against adverse immune responses to AAV gene therapies.

Successful advancement of gene therapy through clinical trials hinges on the development of robust, clinically validated immunoassays and biodistribution studies. These assays, coupled with real-world data, are instrumental in mitigating efficacy and safety roadblocks that can impede progress and, more critically, jeopardize patient safety.

An in-depth understanding of the of the innate and adaptive immune response, predictable translational models and immunosuppression and modulation strategies to mitigate against adverse responses are vital in developing a safe and effective gene therapy product.

This is your opportunity to tackle gene therapy immunogenicity in the ‘here and now’ across, 3 days of in-depth case studies, deep dive workshops and insightful panel discussions.

Join Your Peers to:

icon for bullets

NEW FOR 2024 Immunogenicity Challenges for Gene Editing

Learn about the unique immunogenicity challenges posed by gene editing therapies from CRISPR Therapeutics and Modalis Therapeutics in our brand-new section dedicated to gene editing

icon for bullets

Immune Modulation and Suppression

Hear the latest updates in immune mitigation strategies for local and systemic gene therapies with insights form Spark Therapeutics and Solid Biosciences

icon for bullets

Immune Responses to the Therapeutic Gene

Hear from Regeneron and Roche on their latest data from studies into cellular immune responses into the transgene product and disease specific approaches to overcoming immune these reactions

icon for bullets

Novel Immunoassays, Bioanalytical and Biodistribution technology

Explore freshly validated assays for T cell quantification and AAV biodistribution with talks from  Boehringer Ingelheim and Astellas Gene Therapies 

icon for bullets

AAV Redosing

Look into the future of gene therapies and explore AAV redosing through an immunology lens in a deep-dive workshop with The University of Indiana School of Medicine

 

Event in Numbers

100+

attendees

53%

director level & above attendees

40+

companies

Audience Summary

This summit brings together professionals from preclinical, clinical, translational, bioanalytical, toxicology, and pharmacology development to get the latest insights into overcoming immunogenicity bottlenecks in gene therapy development.

R&D – Discover and digest the latest and greatest in ensuring the safety and efficacy of gene therapies to gain actionable insights for your own gene therapy development efforts.

Business Development – Engage with other business leaders from 40+ industry groups to set up collaborations, secure investment, and unlock future company deals

Service Provider – Position yourself as a leading vendor in the gene therapy development field and win business. Check out our partnership opportunities here

Academia – Leverage the latest data and tech developments from the industry into your own research and network with industry leaders in the field

Testimonials

“Valuable summit attended by gene therapy experts and with up-to-date literature and research presented and discussed.” Charlotte Smerdon, Senior Director – Clinical Operations, Pure Spring Therapeutics

“It was a near flawless execution and a great opportunity for scientific exchange. The networking opportunities were numerous and really added depth to the interactions between attendees.” Karen Quadrini, Director – Biomarkers & Precision Medicine, Passage Bio

“If you work on AAV immunogenicity, this meeting is the best place for a direct contact and exchange of ideas with the most relevant colleagues in the gene therapy industry.” Klaudia Kuranda, Head of Immunology, Spark Therapeutics